Skip to main content

Week in Review: Broncus Stages $200 Million Hong Kong IPO for Pulmonary Devices

Deals and Financings   Broncus Holding, a  Hangzhou  pulmonary medical device company, completed a $200 million IPO in  Hong Kong  at a $1.3 billion valuation; Impact Therapeutics of Nanjing formed a collaboration with Toronto 's Cyclia to validate its novel oncology candidates using Cyclia's data based platform;  COVID-19 Pandemic   Clover, a  Chengdu  company, reported its adjuvanted protein-based COVID-19 vaccine candidate was 100% effective against serious COVID-19 disease in a pivotal global Phase II/II trial;  Trials and Approvals   Akeso reported an NDA for its PD-1/CTLA-4 bi-specific antibody has been accepted for review in  China  for cervical cancer; Suzhou CStone Pharma and US-based EQRx reported their partnered PD-(L)1 antibody doubled PFS in a Phase III trial among NSCLC patients;   Shanghai Hutchmed is starting a Phase III trial of its surufatinib and Junshi's PD-1 in patients with advanced neuroendocrine carcinoma; HighTide Therapeutics, a Shenzhen-Maryland biopharma, published positive data from a US Phase II trial of its novel treatment for NASH and type 2 diabetes; Shanghai CARsgen reported positive data from a China investigator-led trial of its Claudin18.2 CAR-T therapy for digestive system tumors; Beijing InnoCare and  Chengdu 's Keymed announced their  IND  for a CD20xCD3 bispecific antibody was cleared to start China trials in B-cell malignancies.  Stock Symbols: (HK: 2216) (HK: 9926) (HK: 2616) (NSDQ/AIM: HCM; HK: 13) (HK: 2171) (HK: 09969) (HK: 02162)
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.